COPD clinical trials in Tennessee
14 studies for COPD are looking for participants at sites in Tennessee.
Cities in Tennessee
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- Meharry Medical College- Site Number : 8400133, Nashville
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Sep 22, 2026 · NCT07190209An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema
- Fort Sanders Regional Medical Center (StatCare), Knoxville
Recruiting
Ages 40 to 80 · All sexes · Updated Sep 17, 2026 · NCT06035120Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- Chattanooga Research and Medicine- Site Number : 8400026, Chattanooga
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Sep 15, 2026 · NCT07190222A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- Research Site, Chattanooga
- Research Site, Franklin
RecruitingPhase 2
Ages 40 and older · All sexes · Updated Sep 9, 2026 · NCT07082738Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
- Vanderbilt University Medical Center, Nashville
RecruitingPhase 2
Ages 40 and older · All sexes · Updated Sep 4, 2026 · NCT07059091A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
- Research Site, Knoxville
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Sep 3, 2026 · NCT06878261A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
- Research Site, Franklin
- Research Site, Johnson City
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Sep 3, 2026 · NCT06883305A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Clinical Trials Center of Middle Tennessee, LLC, Franklin
- Premier Research Center, LLC, Hendersonville
RecruitingPhase 2/3
Ages 35 to 80 · All sexes · Updated Aug 31, 2026 · NCT07363694A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, Chattanooga
- Research Site, Franklin
- Research Site, Tullahoma
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Aug 26, 2026 · NCT06283966Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators
- The University of Tennessee Graduate School of Medicine, Knoxville
RecruitingPhase 4
Ages 40 and older · All sexes · Updated Aug 17, 2026 · NCT07133880eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
- GSK Investigational Site, Knoxville
RecruitingPhase 3
Ages 40 to 75 · All sexes · Updated Jul 28, 2026 · NCT07177339Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
- Methodist LeBonheur Healthcare, Memphis
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jul 10, 2026 · NCT05181826Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
- GSK Investigational Site, Knoxville
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Apr 9, 2026 · NCT06961214Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
- The Jackson Clinic, PA, Jackson
RecruitingObservational study
Ages 50 and older · All sexes · Updated Aug 5, 2025 · NCT06122077From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.